Hakkı Öztürk

Dr. Hakkı Öztürk


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2026 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
HÖHakkı Öztürk
Hakkı Öztürk
BKBircan Kayaaslan
Bircan Kayaaslan
Background: Antimicrobial resistance is driven by inappropriate antibiotic use, and Türkiye has long shown one of the highest outpatient consumption rates in the WHO European Region. In response, the Ministry of Health implemented stewardship measures from 2014 onward, including the National Action Plan for Rational Drug Use, banning over-the-counter antibiotic sales, integrating e-prescribing with mandatory diagnostic coding, educational initiatives, and audit-feedback systems. This study evaluated temporal trends in primary care antibiotic prescribing in Türkiye between 2011 and 2019 and assessed the influence of these interventions. Methods: We performed a nationwide descriptive analysis using aggregated Prescription Information System (RBS) data covering all family-physician prescriptions (2011–2019). Outcomes included: (i) proportion of prescriptions containing systemic antibiotics (ATC J01), (ii) consumption in DID, (iii) use by ATC-3 class and AWaRe category, (iv) antibiotic share of drug volume and cost, and (v) patterns by age, sex, and diagnosis. Trends were summarized using annual percentages and DID values. The two pre-specified primary outcomes were the annual antibiotic prescription rate and total systemic antibiotic consumption (DID, ATC J01); other indicators were treated as secondary. Because the RBS captures only e-prescribed antibiotics, over-the-counter sales (legal in Türkiye until 2016) are not included. Segmented (interrupted time-series) regression with Newey–West HAC standard errors was applied to test for changes in level and slope at 2016, when prescription-only dispensing was fully enforced and mandatory ICD-10 coding was consolidated within the e-prescribing system. Results: Among 1.17 billion prescriptions, the share containing an antibiotic declined from 34.9 to 23.9%, while consumption fell from 42.3 to 31.9 DID (−25%). Beta-lactams showed the largest reductions, though Watch-group agents still formed nearly half of use in 2019, below the WHO ≥60% Access target. Pediatric prescribing decreased most: use in children aged 0–6 years dropped from 60 to 44% of visits. Elderly patients had the lowest rates. Diagnostic coding shifted away from nonspecific upper-respiratory infections. Antibiotics’ share of outpatient drug costs fell from 10.7 to 4.7%, yielding an estimated 1.7 billion TL savings in 2018. Segmented regression confirmed an acceleration of the decline after 2016: the slope changed by −0.69 percentage points/year for the prescription rate (95% CI − 1.44 to +0.06; p = 0.07) and by −0.80 DID/year for total consumption (95% CI − 0.88 to −0.72; p < 0.001) versus the pre-2016 trajectory. Conclusion: Türkiye achieved major reductions in primary care antibiotic use within a decade, temporally concordant with multifaceted stewardship policies whose individual contributions cannot be isolated by this descriptive design. However, outpatient levels remain above many EU countries, and Watch-group use is still high. Further progress requires stronger guideline adherence, prioritization of Access antibiotics, and wider use of point-of-care diagnostics.

22 May 2026 in Medicine
Verified
Journal Article
Open access
HAHatice Ağir
Hatice Ağir
AÇAydın Çifci
Aydın Çifci
TKTurgut Kültür
Turgut Kültür
HÖHakkı Öztürk
Hakkı Öztürk
DFDUYGU FELEK
DUYGU FELEK
ÖEÖzcan EREL
Özcan EREL
Fibromyalgia syndrome (FMS) is a common but frequently overlooked cause of chronic pain in patients with chronic kidney disease, particularly those undergoing hemodialysis (HD). In addition to its impact on quality of life (QoL), FMS may be associated with oxidative stress pathways involved in chronic kidney disease pathophysiology. However, the relationship between FMS and thiol/disulfide homeostasis in HD patients remains unclear. This study examined the association between FMS, QoL, and thiol/disulfide parameters in a multicenter HD population. In this multicenter cross-sectional study, 126 HD patients (66 with FMS and 60 without FMS) from 2 dialysis centers in Turkey were evaluated between July and December 2024. FMS was diagnosed using the 2016 American College of Rheumatology criteria. Demographic data, laboratory parameters, QoL measures (short form-36 [SF-36], Fibromyalgia Impact Questionnaire [FIQ], Brief Illness Perception Questionnaire), and oxidative stress markers (native thiol, total thiol, disulfide, and related ratios) measured by automated spectrophotometry were analyzed. Group comparisons were performed using appropriate statistical tests. Correlations were assessed using Spearman analysis. Multivariable binary logistic regression was conducted to identify variables independently associated with FMS. Post hoc power analysis demonstrated adequate statistical power (87.3%, α = 0.05). Native thiol (242.35 ± 40.45 vs 225.36 ± 40.01 μmol/L, P = .019), total thiol (284.39 ± 46.60 vs 264.76 ± 46.29 μmol/L, P = .019), and disulfide (21.02 ± 3.74 vs 19.70 ± 3.62 μmol/L, P = .047) levels were higher in patients with FMS, whereas thiol/disulfide ratios did not differ between groups. FMS patients had significantly higher FIQ scores and lower SF-36 domain scores, indicating poorer QoL. Weak correlations were observed between native thiol and FIQ ( r = 0.202) and between total thiol and SF-36 mental health (ρ = −0.242). In multivariable analysis, total thiol remained independently associated with FMS (OR = 1.009, P = .023), although explained variance was modest (Nagelkerke R 2 = 0.058). FMS in HD patients is associated with impaired QoL and modest alterations in thiol-related oxidative parameters without a shift in thiol/disulfide ratios. These findings should be interpreted cautiously given the cross-sectional design. Prospective studies are needed to clarify underlying mechanisms.

28 August 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
HÖHakkı Öztürk
Hakkı Öztürk
ÇIÇiğdem Ikhlef
Çiğdem Ikhlef
BABerrak Itır Aylı
Berrak Itır Aylı
Veysel Baran TomarVeysel Baran Tomar
Veysel Baran Tomar
BEBartu Ediz
Bartu Ediz
MAMehmet Deniz Aylı
Mehmet Deniz Aylı
Background/Objectives: Secondary hyperparathyroidism (SHPT) is a prevalent complication of end-stage kidney disease. Although etelcalcetide has demonstrated short-term superiority over cinacalcet in randomized trials, real-world comparative data beyond 12 months remain scarce. This study compared the long-term effectiveness of etelcalcetide versus cinacalcet in hemodialysis patients over 24 months using propensity score matching. Methods: This multicenter retrospective study screened 457 hemodialysis patients across five centers in Türkiye. Propensity score matching on age, sex, hemodialysis vintage, and baseline intact parathyroid hormone (iPTH) yielded balanced cohorts of 21 versus 21 for 12-month and 14 versus 14 for 24-month analyses. The primary outcome was percentage change in iPTH from baseline (%ΔPTH). Secondary outcomes included responder rates, KDIGO target achievement, response trajectory classification, and depth-of-response analysis. Results: At 12 months, etelcalcetide achieved significantly greater iPTH reduction (%ΔPTH: −50.5 ± 25.6% vs. −29.7 ± 40.6%; p = 0.047), with effect sizes increasing from medium to medium–large at 24 months (Cohen’s d: −0.612 to −0.779). Sustained response (≥30% iPTH reduction at both timepoints) was significantly higher with etelcalcetide (78.6% vs. 28.6%; p = 0.021), as was deep response (≥75% reduction) at 24 months (57.1% vs. 14.3%; p = 0.046). At 24 months, etelcalcetide demonstrated significantly lower serum calcium (p = 0.015), calcium–phosphate product (p = 0.023), and superior phosphate target attainment (85.7% vs. 28.6%; p = 0.004). Inter-patient response variability was nearly three-fold lower with etelcalcetide (CV: 42% vs. 151%). Conclusions: Etelcalcetide provided significantly greater, more sustained, and more consistent iPTH suppression than cinacalcet over 24 months, with additional benefits in mineral metabolism control. These findings support etelcalcetide as a potent therapeutic option for SHPT in hemodialysis patients and warrant confirmation in larger prospective trials.

8 September 2026 in Viruses
Verified
Journal Article
Open access
PDF file
HÖHakkı Öztürk
Hakkı Öztürk
BABerrak Itır Aylı
Berrak Itır Aylı
The 2026 Bundibugyo virus disease outbreak in the Democratic Republic of the Congo and Uganda, the first Ebola-related PHEIC caused by a species lacking a licensed vaccine, has been accompanied by an information crisis marked by conspiracy-driven violence against response teams and destruction of treatment centres. Understanding what populations actually seek to know during such events is essential for designing effective communication strategies, yet the content of public information demand during Ebola outbreaks has not been systematically characterised. We combined Google Autocomplete query extraction (7347 unique queries from 83 seed terms in English and French) with Google Trends temporal analysis across six Ebola outbreaks (2014–2026). The autocomplete suggestion landscape was dominated by risk quantification and transmission concerns. Google Trends temporal analysis showed moderate to strong co-movement between misinformation-related search terms and overall Ebola search interest (Spearman ρ = 0.359–0.697, nominal p < 0.001). Substantial differences emerged between the English-language and French-language suggestion sets: French-language suggestions contained six times more misinformation and conspiracy content (4.9% vs. 0.8%) and nearly nine times more fear-related content (3.5% vs. 0.4%) than English-language suggestions. These findings demonstrate that infodemic management strategies designed in Anglophone contexts are inadequate for the populations most at risk and should inform linguistically adapted interventions for the ongoing response.